Abstract: Hepatitis C virus (HCV) infection can cause renal injury, increase the all-cause and cardiovascular mortality in the dialysis population, and decrease the graft survival among kidney transplant patients. Control of HCV infection is therefore critical to these patients. Interferon-based therapy is rarely used among dialysis and kidney transplant patients due to its frequent side effects, low virological responses, higher rejection and graft failure. The presence of highly efficacious, well-tolerated direct-acting antiviral agents provides an ideal way to cure HCV infection in chronic kidney disease patients.

Key words: Hepatitis C virus, Chronic kidney disease, Hemodialysis, Kidney transplant, Direct-acting antiviral agents